Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcrc.2015.09.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inavolisib: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.
View Article and Find Full Text PDFNonnegligible cascading impacts of global urban expansion on net primary productivity.
PNAS Nexus
January 2025
Key Laboratory of Geographic Information Science (Ministry of Education), School of Geographic Sciences, East China Normal University, Shanghai 200241, China.
Accelerated global urban expansion not only directly occupies surrounding ecosystems, but also induces cascading losses of natural vegetation elsewhere through cropland displacement. Yet, how such effects alter the net primary productivity (NPP) worldwide remains unclear. Here, we quantified the direct and cascading impacts of global urban expansion on terrestrial NPP from 1992 to 2020 and projected the impacts under the shared socioeconomic pathways framework by 2100.
View Article and Find Full Text PDFFlurpiridaz F 18: First Approval.
Am J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFRetraction notice to "Degradation of cefadroxil drug by newly designed solar light responsive alcoholic template-based lanthanum ferrite nanoparticles" [Environ. Res. 231P3 (2023) 116241].
Environ Res
January 2025
Department of Biology, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh, 11671, Saudi Arabia.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/locate/withdrawalpolicy).
View Article and Find Full Text PDFComment on "Assessing Corneal Tomographic Changes in Fuchs Endothelial Corneal Dystrophy Over 1 year: Scheimpflug Versus Anterior Segment Optical Coherence Tomography".
Cornea
January 2025
Department of Eye and Vision Science, University of Liverpool, Liverpool, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!